Branch retinal vein occlusion following infliximab treatment: Case report;Oclusão de ramo venoso da retina associado ao uso de infliximabe: Relato de caso

Arquivos Brasileiros de Oftalmologia

Volumn 74, Issue 3, 2011, Pages 214-216

  Diniz, Bruno ^a   Barbosa, Carolina Pelegrini ^a   Regatieri, Caio Vinicius ^a   Rodrigues, Eduardo B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antibodies; Case reports; Monoclonal administration, dosage; Monoclonal adverse effects; Retinal vein occlusion chemically induced; Rheumatoid arthritis drug therapy

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MIDDLE AGED; RETINA VEIN OCCLUSION; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MIDDLE AGED; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

EID: 81355139463     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492011000300015     Document Type: Article

References (10)

1. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28(2):117-44.
2. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005; 23(4):469-74.
3. Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33(2):387-406, xi.
4. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003; 48(8):2224-33.
5. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13 Suppl 4:16-22; discussion 38.
6. Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. Gastroenterology. 2003;125(5)1544-46.
7. ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ. 2003;326(7389):579.
8. Veerappan SG, Kennedy M, O'Morain CA, Ryan BM. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol. 2008;20(6):588-89.
9. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-63.
10. Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S. Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. J Orthop Sci. 2010;15(1):57-63.